MEMORANDUM FOR ST
ATTN: SANDRA VALTIER

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

1. Your paper, entitled A Synopsis of Personalized Medicine Projects within the United States Air Force presented at/published to San Antonio Military Health System and Universities Research Forum (SURF), TX, 16 June 2017 in accordance with MDWI 41-108, has been approved and assigned local file #17235.

2. Pertinent biographic information (name of author(s), title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.

3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist’s Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.

4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC
Director, Clinical Investigations & Research Support

17 MAY 2017
INSTRUCTIONS

USE ONLY THE MOST CURRENT 59 MDW FORM 3039 LOCATED ON AF E-PUBLISHING

1. The author must complete page two of this form:
   a. In Section 2, add the funding source for your study (e.g., 59 MDW CRD Graduate Health Sciences Education (GHSE) (SGS O&M); SGS R&D; Tri-Service Nursing Research Program (TNSRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.)
   b. In Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication. Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.

2. Print your name, rank/grade; sign and date the form in the author's signature block or use an electronic signature.

3. Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.

4. Attach a copy of your abstract, paper, poster and other supporting documentation.

5. Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.

6. On page 2, have either your unit commander, program director or immediate supervisor:
   a. Print their name, rank/grade; title; sign and date the form in the approving authority's signature block or use an electronic signature.

7. Submit your completed form and all supporting documentation to the CRD for processing (59cdrupubsres@us.af.mil). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Prepublications and Presentations Section at 292-7141 for assistance.

8. The 59 CRD/Prepublications and Presentations Section will route the request form to clinical investigations, 502 ISG/JAC (Ethics Review) and Public Affairs (59 MDWPA) for review and then forward you a final letter of approval or disapproval.

9. Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.

10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Prepublications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CRC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.

11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research and technical documents will not be forwarded to the 502 ISG compliance office for an ethics review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

   For presentations before professional societies and like organizations, the 59 MDW Public Affairs Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

   If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

   If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

   If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/JAC.

   If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

   If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISG/JAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-7595/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presentee(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DOD 3216.02_AF 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401_IP.

"The experiments reported herein were conducted according to the principles set forth in the National Institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1965, as amended."
TO: CLINICAL RESEARCH
FROM: Sandra Valtier, PhD, 59MDW/ST
GME/GHSE STUDENT: [ ] YES [ ] NO
PROTOCOL NUMBER: [ ] YES [ ] NO

PROCCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

1. TITLE OF PROTOCOL:

2. PROTOCOL TITLE: A SYNOPSIS OF PERSONALIZED MEDICINE PROJECTS WITHIN THE UNITED STATES AIR FORCE

3. FUNDING RECEIVED FOR THIS STUDY? [ ] YES [ ] NO
FUNDING SOURCE: SG5 R&D

4. DO YOU NEED FUNDING SUPPORT FOR PUBLICATION PURPOSES? [ ] YES [ ] NO

5. PROTOCOL TITLE: [NOTE: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.]

6. TITLE OF MATERIAL TO BE PUBLISHED OR PRESENTED:

7. MATERIAL IS FOR: [ ] DOMESTIC RELEASE [ ] FOREIGN RELEASE

8. IS THIS MATERIAL CLASSIFIED? [ ] YES [ ] NO

9. IS THIS MATERIAL SUBJECT TO ANY LEGAL RESTRICTIONS FOR PUBLICATION OR PRESENTATION THROUGH A COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENT (CRADA), MATERIAL TRANSFER AGREEMENT (MTA), INTELLECTUAL PROPERTY RIGHTS AGREEMENT ETC.? [ ] YES [ ] NO [NOTE: If the answer is YES then attach a copy of the Agreement to the Publications/Presentations Request Form.]

10. MATERIAL IS FOR: [ ] DOMESTIC RELEASE [ ] FOREIGN RELEASE

11. MATERIAL IS FOR: [ ] DOMESTIC RELEASE [ ] FOREIGN RELEASE

12. HAVE YOUR ATTACHED RESEARCH/TECHNICAL MATERIALS BEEN PREVIOUSLY APPROVED TO BE PUBLISHED/PRESENTED?
[ ] YES [ ] NO

13. EXPECTED DATE WHEN YOU WILL NEED THE CRO TO SUBMIT YOUR CLEARED PRESENTATION/PUBLICATION TO DTIC

14. 59 MDW PRIMARY POINT OF CONTACT (Last Name, First Name, M.I., email)
Valtier, Sandra. Sandra.Valtier.civ@mail.mil

15. DUTY PHONE/PAGER NUMBER
210-292-0500

16. AUTHORSHIP AND CO-AUTHOR(S): List in the order they will appear in the manuscript.

<table>
<thead>
<tr>
<th>LAST NAME, FIRST NAME AND M.I.</th>
<th>GRADE/RANK</th>
<th>SQUADRON/GROUP/OFFICE SYMBOL</th>
<th>INSTITUTION (If not 59 MDW)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Valtier, Sandra</td>
<td>GS14</td>
<td>59MDW/ST</td>
<td></td>
</tr>
<tr>
<td>Chaudry, Jalani G.</td>
<td>Ctr</td>
<td>59MDW/ST</td>
<td></td>
</tr>
<tr>
<td>Lott, Lisa</td>
<td>Ctr</td>
<td>59MDW/ST</td>
<td></td>
</tr>
<tr>
<td>Caballero, Manuel</td>
<td>GS12</td>
<td>59MDW/ST</td>
<td></td>
</tr>
<tr>
<td>Brock, Matthew</td>
<td>MAJ</td>
<td>59 MDSP / SGMSS</td>
<td>SAMHS</td>
</tr>
</tbody>
</table>

17. IS A 502 JS/GJC ETHICS REVIEW REQUIRED (JER DOD 5500.07-R)? [ ] YES [ ] NO

18. AUTHOR'S PRINTED NAME, RANK, GRADE
Sandra Valtier, Ph.D.

19. AUTHOR'S SIGNATURE
Valtier Sandra 1230996403

20. DATE
May 11, 2017

21. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE
William C. Terry

22. APPROVING AUTHORITY'S SIGNATURE
Terry William Chris 11552859093

23. DATE
May 11, 2017

PREVIOUS EDITIONS ARE OBSOLETE

Page 2 of 3 Pages
| **TO:** Clinical Research Division  
59 MDW/CRD  
Contact 292-7141 for email instructions | **DATE RECEIVED** | **ASSIGNED PROCESSING REQUEST FILE NUMBER** |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>May 11, 2017</td>
<td>17235</td>
</tr>
</tbody>
</table>

26. **DATE REVIEWED**  
12 May 2017  

28. **AUTHOR CONTACTED FOR RECOMMENDED OR NECESSARY CHANGES:**  
☐ NO ☐ YES If yes, give date. ☐ N/A  

29. **COMMENTS**  
☐ APPROVED ☐ DISAPPROVED  

The abstract is approved.  

<table>
<thead>
<tr>
<th>30. <strong>PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</strong></th>
<th>31. <strong>REVIEWER SIGNATURE</strong></th>
<th>32. <strong>DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Rocky Calcote, PhD, Clinical Research Administrator</td>
<td>CALCOTE ROCKY D. 1178245644</td>
<td></td>
</tr>
</tbody>
</table>

33. **DATE RECEIVED**  

35. **COMMENTS** ☐ APPROVED (In compliance with security and policy review directives.) ☐ DISAPPROVED  

36. **PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER**  

37. **REVIEWER SIGNATURE**  

38. **DATE**  

39. **DATE RECEIVED**  
May 16, 2017  

41. **COMMENTS** ☑ APPROVED (In compliance with security and policy review directives.) ☐ DISAPPROVED  

<table>
<thead>
<tr>
<th>42. <strong>PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER</strong></th>
<th>43. <strong>REVIEWER SIGNATURE</strong></th>
<th>44. <strong>DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Kevin Inuma, SSgt/E-5, 59 MDW Public Affairs</td>
<td></td>
<td>May 16, 2017</td>
</tr>
</tbody>
</table>

45. **DATE RECEIVED**  
May 16, 2017  

47. **COMMENTS** ☐ APPROVED ☐ DISAPPROVED  

48. **PRINTED NAME, RANK/GRADE, TITLE OF REVIEWER**  

49. **REVIEWER SIGNATURE**  

50. **DATE**
A SYNOPSIS OF PERSONALIZED MEDICINE PROJECTS WITHIN THE
UNITED STATES AIR FORCE

Sandra Valtier, Ph.D., G. Jilani Chaudry, Ph.D.,
Lisa Lott, Ph.D., Manuel Caballero, M.S., and Matthew S. Brock, M.D.
Center for Advanced Molecular Detection (CAMD)
Office of the Chief Scientist
Science & Technology, 59th Medical Wing
JBSA-Lackland, TX

The United States Air Force's Personalized Medicine (PM) program incorporates research in genetics, pharmacogenomics and proteomics to understand and optimize the prevention, diagnosis and treatment of disease. At the Center for Advanced Molecular Detection (CAMD), several ongoing analyses evaluate individual genetic variations or patterns of variations with the potential as diagnostic, predictive, or prognostic markers, and with the long-term goal of facilitating individualized treatment regimes.

A study elucidating the genetic epidemiology of Type 2 Diabetes Mellitus (T2DM) in the Military Health System (MHS) population provides evidence of single nucleotide polymorphisms (SNPs) associated with an enhanced risk of future Type 2 Diabetes Mellitus. Results indicate the majority of significant T2D risk-conferring SNPs were present in a younger stratified age group and have been shown to influence β-cell function through transcription repression or transporter expression in the secretory vesicles of pancreatic beta-cells. A detailed statistical analysis is in progress and includes subcategorization of the MHS cohort to reveal associations with defined subcategories, such as age group, gender, race, medication response, and any consequent pathologies of T2DM. The ability to identify genetic markers in service members and target appropriate lifestyle interventions, far in advance of actual disease onset, has great potential to reduce disease burden and preserve the military readiness mission. Further evaluation of the utility of genetic variation will also be discussed based on pharmacogenomic therapeutic strategies specifically aimed at delaying diabetes progression.

The CAMD is also collaborating with San Antonio Military Medical Center to investigate individual risk and protective factors associated with post-traumatic stress disorder (PTSD) in a cohort of U.S. military personnel. An overview of the project will be provided consisting of four parallel but distinct tracks: 1) Analysis of 15 SNPs that putatively associate with PTSD or certain disorders of affect; 2) Evaluation of the Serotonin transporter gene (SLC6A4) promoter size heterogeneity and putative association with
PTSD; 3) Measurement of relative telomere length to elucidate any correlation with PTSD susceptibility; and 4) Determination of the methylation status of genomic DNA to discern any patterns that may correlate with susceptibility to PTSD.

Investigation of genetic risk factors for severe cutaneous adverse drug reactions (ADRs) are ongoing, with plans for a prospective study using whole genome sequencing and transcriptome studies in patients with Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A secondary goal is to create a tissue repository to aid in future studies examining ADRs.

The final study for discussion evaluates the association of 13 SNPs with risk for musculoskeletal (MSK) injuries, including osteoarthritis, rheumatoid arthritis, and ligament tears. The first phase of the MSK study is underway and examines samples procured from commercial sources. The next phase includes the enrollment of military trainee personnel to identify genetic markers that may afford early identification of risk of injury in this population, with the long-term goal of individualizing training regimes to minimize the frequency of MSK injury.

Disclaimer: The views expressed are those of the presenters and do not reflect the official views or policy of the Department of Defense or its Components. The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DoDI 3216.02_AFI 40-402, Protection of Human Subjects in Biomedical and Behavioral Research.